美国安进地舒单抗注射液治疗效果好吗

Amgen was founded in 1980 by a group of scientists and venture capitalists. Amgen is principally engaged in the discovery, development, production and sales of innovative drugs for human use, and is committed to exploring the potential of biotechnology for the treatment of patients with serious diseases. By leveraging cutting-edge human genetics and other tools, Amgen seeks to unravel the complexity of disease and lay the foundation for understanding human biology. So is the injection produced by Amgen in the United States effective?

Desosumab is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. A one-year, double-blind, randomized controlled phase III clinical trial DECIDE (Determining Efficacy: Comparison of Initiating Denosumab versus alEndronate) compared the effectiveness and safety of this product and alendronate. A total of 1189 postmenopausal women were enrolled. The average baseline T-score of the lumbar spine of the enrolled patients was -2.6, and the average age was 64 years old.

Patients were randomly divided into: treatment group (60 mg subcutaneous injection of this product, once every 6 months, n = 594), control group (oral alendronate sodium 70 mg, once every 6 months, n = 595). All subjects were supplemented with 500 mg of calcium every day, and the dose of vitamin D was adjusted according to plasma 25-hydroxyvitamin D levels. After 12 months, it can be observed that the BMD of both groups increased at all detection sites (hip, spine, femoral neck, trochanter, and distal 1/3 of the radius), but the increase in the treatment group was more significant than that of the control group (the primary endpoint of the total hip BMD increased by 3.5 and 2.6, respectively, P < 0. 000 1). The incidence of adverse reactions was similar between the two groups. A patient survey showed that the majority of patients (77%) preferred to receive subcutaneous denosumab twice a year.

In addition, the editor reminds patients that denosumab can only be injected subcutaneously, not intravenously, intramuscularly, or intradermally. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Bone metastases from solid tumors: 120 mg subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

In summary, the therapeutic effect is good, and patients can take the medication safely under the doctor's advice.

Recommended related hot articles: /newsDetail/91115.html